glp-1 c elegans Mutation of GLP-1/Notch RAM domain results in a strong phenotype Neuronal MML-1/MXL-2 regulates systemic aging

However, for those who can, we encourage subscribing and listening to the original content for a more engaging and immersive experience

They obtained baseline measurements for these outcomes plus final measurements at the end of the 12-week study period [31]

All authors discussed the results and contributed to writing and editing the final manuscript

Key GLP1 therapies are integrated into national insurance schemes, and the countrys aging population underscores its strategic importance in diabetes and obesity management

New survey documents patients experiences What does it feel like to take GLP-1s

Lilly is building a multi-engine growth machine: Alzheimer's Treatment Kisunla (Donanemab) - FDA-approved for early Alzheimer's, first proven to slow cognitive decline Represents a breakthrough in neurodegenerative disease treatment Oncology & Immunology Verzenio (breast cancer): $1.47B in Q3 2025 (+7% YoY) Jaypirca and Omvoh expanding in oncology and autoimmune markets Radiopharmaceutical investments through Point Biopharma ($1.4B acquisition) and Aktis Oncology partnership Pipeline Depth 40+ programs in Phase 2/3 across neuroscience, immunology, and cardiology Recent acquisitions: Scorpion Therapeutics, SiteOne Therapeutics, Adverum Biotechnologies Lilly isn't a one-trick pony